Novo Nordisk’s weight loss drug Wegovy slashes risk of serious heart events

default_image

The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S. 

Leave a Reply

Your email address will not be published. Required fields are marked *